Abstract: INTRODUCTION Treatment of malignant pleural mesothelioma (MPM) remains a clinical challenge. The aim of this study was to identify selection factorsfor allocation of MPM patients to multimodal therapy based on survival data from 12 years of experience. METHODS Eligible patients had MPM of all histological subtypes with clinical stage T1-3 N0-2 M0. Induction chemotherapy consisted of cisplatin/gemcitabine (cis/gem) orcisplatin/pemetrexed (cis/pem), followed by extrapleural pneumonectomy (EPP).Multivariate analysis was performed to assess independent prognosticators for overall survival (OS). A Multimodality Prognostic Scorewasdeveloped based on clinical variablesavailable before surgery. RESULTS From May 1999 to August 2011, 186 MPM patients were intended to be treated with induction chemotherapy followed by EPP. Hematologic toxicity was significantly less frequent after cis/pemcompared to cis/gem, but no difference in response or OS between the regimens.128 patients underwent EPP with a30-day mortalityof4.7%. 52% percent of the patients received adjuvant radiotherapy. The median OSof patients undergoing EPP was significantly longer with 22months (95%CI:20-24) as compared to 11 months (9-12) for patients treated without EPP.Aprognostic score was defined considering tumor volume,histology, CRP,andresponsetochemotherapythat identified patient groupsnot benefittingfrom multimodality treatmentwhich was confirmed in an independent cohort. CONCLUSION Patients receiving induction chemotherapy followed by EPP for MPM of all histological subtypes and irrespective of nodal statusshowed a median survival of 22months. A prognostic score is proposed to help patient allocation for surgery after validation in an independent cohort. 
Results: From May 1999 to August 2011, 186 MPM patients were intended to be treated with induction chemotherapy followed by EPP. Hematologic toxicity was significantly less frequent after cis/pemcompared to cis/gem, but no difference in response or OS between the regimens.128 patients underwent EPP with a30-day mortalityof4.7%. 52% percent of the patients received adjuvant radiotherapy. The median OSof patients undergoing EPP was significantly longer with 22months (95%CI:20-24) as compared to 11 months (9-12) for patients treated without EPP.Aprognostic score was defined considering tumor volume,histology, CRP,andresponsetochemotherapythat identified patient groupsnot benefittingfrom multimodality treatmentwhich was confirmed in an independent cohort.
Conclusion: Patients receiving induction chemotherapy followed by EPP for MPM of all histological subtypes and irrespective of nodal statusshowed a median survival of 22months.
A prognostic score is proposed to help patient allocation for surgery after validation in an independent cohort. improved quality of complete macroscopic resection, have changed the scepticalattitude towards this disease. This is a result of rising experiences with multimodality (MM) treatment strategies associated with a median survival up to 59 months in selected patients [1] [2] [3] [4] . One of the most challenging questions is the selection of patients for aggressive treatment, considering the limited prognosis of MPM patients in general.To identify patient subgroupsnot benefitting from MM therapy and therefore to exclude those from surgery would be desirable.
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In the presentreport we analysedone of the largest series ofconsecutively treated patients with induction chemotherapy (cis/gemor cis/pem) followed by extrapleural pneumonectomy (EPP). We decided to establisha new Multimodality Prognostic Scoreusing clinical variables for the decision to perform surgery. Surgery(EPP) was performed within 6 weeks after completion of the last cycle of chemotherapy as described previously 6 .Final pathological staging was carried out following the TNM staging system 7 .
Materials and Methods

Patients and Indications
MPM
Radiotherapy was performed according to definite tumor stage and if high-risk zonesweredefined by the operating surgeon or according to SAKK 17/04treatment protocol.
Different radiation techniques and doses were applied over the years (3D-conformal radiotherapy and IMRT).Overall 67 patients (52%) received adjuvant radiotherapy (12 patients in IMRT technique) after induction chemotherapy and EPP.
Analysis of data
Data were collected from medical records archived in our data management program KISIM All consecutive patients intended to be treated with inductionchemotherapy and EPP were retrospectively analysed for toxicity of chemotherapy and survival. Toxicities assessed were grade °III/°IVhaematological toxicity, grade °III/°IVnephrotoxicity, and unscheduled hospitalizations due to chemotherapy.
Response to chemotherapy was evaluated by modified RECIST criteria by one independent observer (T.F) 8 in 128 cases with available pre and post chemotherapy imaging as was the tumor volume (T.F., D.N.-K.) which was assessed by the help of a semi-automated dedicated software (Myrian®; Intrasense, Paris, France) asdescribed previously 9 .
Patients undergoing EPP after induction chemotherapy were evaluated for putative prognostic factors for overall survival (OS)according to Simms et al. 10 . Continuous variables were dichotomized by data driven approaches. The putative factors described for an association with outcomewere: sex, age ( 61 years vs. >61 years), exposure to asbestos, smoking, weight mg/lbefore chemotherapy,and progressive diseaseafter chemotherapy. A second score using the same variables without progressive disease after chemotherapy was tested in order to evaluate factors being available at initial patient evaluation.
The predictive power of our new MMPS was compared to the existing EORTC score at one and two years using time-dependent ROC curve estimation using the R package
.The prognostic impact of MMPSwas further evaluated in the intention to treat cohort without surgery (n=37)as well as in an independent cohort of patients treated at the Division of Thoracic Surgery, University Hospital in Vienna (n=22) with the same treatment approach of induction chemotherapy followed by EPP. (65%) were treated withcis/pem chemotherapy,onepatient received cisplatin plus vinorelbine.
Results
From
There was significantly less °III/°IVhaematological toxicity at day 8 after cis/pemchemotherapy (p<0.0005)in comparison to cis/gem, whilethere wereno significant differences in nephrotoxicity or unscheduled hospitalisations.Response after chemotherapy wasassessed in 128cases:60patients had stable disease (SD),33progressive disease (PD), and 35partial response (PR), no complete response was observed. There was no significant difference in response between the two chemotherapy regimens: 66% cis/gem with SD or PR versus77% cis/pem(p=0.7). Also the changes of tumorvolume after chemotherapy did not 17-26)) (p=0.02) ( Figure 1A ).The chemotherapy regimen applied had no impact on OS ( Figure 1B ). 58 patients were excluded from radical resection after induction chemotherapy.
The most frequent reason for exclusion was multi-level chest wall infiltration (n=26),another Side effects of radiotherapy included dysphagia (n=16), nausea (n=26), emesis (n=19), radiation dermatitis (n=9), fatigue (n=17), but also more important complication such as esophagitis (n=6).
In addition to the independent prognosticators of our multivariate analysis CRPand RECIST,we includedtumor volume and histological subtype into our proposed
MMPSaccording to reports from the literature 12, 15 .
The MMPSrevealed that patients with a score >3had a significantly shorterOS(p<0.0005) ( Figure 3A) . The same was observed using the score without the response variable (data not shown).Multivariate analysis including our MMPSrevealed that the score was a strong independent prognosticator (table 3 ). The score was tested also in patients of the ITT group(n=37) that did not receive EPP after induction chemotherapyand validated in an independent cohort being treated with induction chemotherapy followed by EPP at the University Hospital Vienna (n=22), both cohorts not being significantly different in terms of age, pre chemotherapy volume, pre chemotherapy histological subtype, and RECIST.In these two cohorts patients with score 0 showed a significantly longer OS( Figure 3B and 3C ), but median survival could not be calculated for all scores in the Vienna cohort, because 10 of 22 patients had to be censored in survival analysis.
The comparison of the present scores to EORTC score using ROC analysis at two years showed that the MMPS (3 and 4 variables) demonstrated a better predictive power for OS thanthe EORTC Score (Supplementary figure 2) . Similar results were obtained for one year (data not shown).
Discussion
The present analysis isone of the largest series of induction chemotherapy followed by EPP and confirms a median survival of 22 months after induction chemotherapy with initiallycis/gem and in the later period cis/pem followed by EPP for MPM of all histological were not able to demonstrate with existing scores as the EORTC score.
When we introduced induction chemotherapy followed by EPP as a treatment modality for MPM patients 12 years ago, we postulated that upfront chemotherapy may possibly downstage the tumor and hence increase resectability of MPM and therefore improve survival. In our initial pilot study we observed a promising median overall survival time of 22 months which was later confirmed by our Swiss multicentre study 2 . Since then this concept has been adapted by multiple other mesothelioma centersworldwide with comparable outcome 3, 4 .However, overall survival for the whole cohort plateaued at nearly 2 years (reviewed in Cao et al. 2010 16 ). This is most likely related to the fact that eligibility criteria were wide. In additionpatients'selection became less stringent over time and patients with more advanced disease (proportion of pT4 10% in the present cohort) orcomorbidities were accepted. This was felt to be justified by the lack of alternatives and the fact that we were able to perform this complex treatment with relatively low mortality and morbidity. Patients were accepted for induction chemotherapy and later for resection evenifno response to chemotherapy occurred. However, our current analysis shows, that such "rescue procedures" resulted in no long-term benefit and we might have observed better outcome with less wide inclusion criteria.
The currentanalysis represents12years' experience with cisplatin-based induction chemotherapy followed by EPP in patients with mesothelioma.To our knowledge, although not randomized, this is the first series reporting a large cohort of patients who received platinum-based chemotherapy in combination with either gemcitabine or pemetrexed asinduction chemotherapyfollowed by EPP. In our analysis we focused not primarily on identification of prognostic factors based on pathological staging but rather on prognostic One particular patient subgroup of interest isthe one responding to induction chemotherapy.
Indeed, the response to chemotherapy significantly influenced OS-2/3 of the patients responded with either PR or SD afterinduction chemotherapy and survived significantly longer. Response to chemotherapy turned out to beeven an independent prognosticator in our multivariate analysis,which could help to select patients for surgery.The use of cis/gem compared to cis/pem had no influence either on response to chemotherapy measured by RECIST oron survival. But it was found that toxicity differsbetween the two regimens and °III/°IV haematological toxicity was significantly lower after cis/pem.
Since Pass et al. proposed to use tumor volume as a prognostic factor for mesothelioma patients' survival 13 , it has been confirmed by several other groups 12 . Modern computerbased software using chest CT facilitates tumormeasurement in a reliable and reproducible way 9 . In addition, low C-reactive protein level (CRP)was identified as independent prognosticator for longer OS. CRP as an easy to measure marker of inflammatory response has been validated already in various other cancers as a prognostic marker 17, 18 . The reason why CRP is a prognostic value in cancer patients is not completely understood but might be related to higher tumor aggressiveness as it has been shown also for other type of tumors, eg.
melanomaand was already demonstrated to be prognostic in the context of MPM 19 .
Other prognosticators such as histological subtype ormediastinal lymph node involvement cohorts tested the longest OS, whereas patients with a score of 3 or higher had OS as dismal as untreated MPM patients.Furthermore, this was not only confirmed in our ITT group of patients not undergoing EPP, but also in a second independent cohort of patients treated with the same protocol in Vienna.
In the last years a clear trend to replace EPP by (extended) pleurectomy/decortication (P/D), especially for early stages, exists.We hypothesize, that this score may be applicable to all macroscopic complete resections (MCRs) within a multimodality concept, as a small subset of patients excluded from EPP received P/D (n=20) instead and here we could observe a trend ofsurvival prognostication by our MMPS score (data not shown).
Although EORTC Score has been validated in several cohorts 24 , we were not able to demonstrate any significant prognostic impact on OS.This may be explained by our median EORTC score which was 0.6 (range 0-2.34) and quite low in comparison to other groups. The higher scores in the other groups are probably due to the fact that these cohorts were receiving chemotherapy alone in most cases and therefore had advanced disease and worse performance status.In comparative ROC analysis our MMPS score performed better than EORTC score. Besides the retrospective analysis of our data and the fact that therefore not all data were available for the whole patient cohort, we are aware that AUC of 69% does not qualify our MMPS immediately as a predictive test for patient selection. However, confirmation in an independent cohort and in a patient cohort intended to be treated warrants further prospective evaluation. With a specificity of 100% of Score 3 and 4 (no survivor had this score) and a survival resembling untreated MPM patients, we feel that these patients should not be recommended to proceed to MCR in a multimodality concept, which will now be further evaluated prospectively.
Conclusion: Overviewing our 12 years' experience with induction chemotherapy with cis/gem and cis/pemfollowed by EPP for MPM patients of all histological subtypes including N2
disease,we report a median OS close to two years. The non-randomized comparison of both chemotherapy regimens showed significant reduced haematological toxicity in favour of cis/pem but no advantage in response or overall survival. A new Multimodality Prognostic
Score was developed and validated in an independent cohort considering clinical variables already available before surgerywhich allowsidentification ofmesothelioma-patients who would not get any relevant benefit from an intensified therapy. Additionally biological markers are intensively explored at our institution. Among these, tumor proliferation index is a robust biomarker, and was significantly associated with clinical outcomes and tumor volume. We are also validating the previously identifiedprognostic microRNA score 25 in our patient cohort. This is particularly interesting as microRNAs are also potential blood based biomarkers 26 . Thus, we may improve the prognostic value by integrating these factors into our Multimodality Prognostic Score. The conceptwill be further validated prospectively. 
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